Bilateral transient hearing loss associated with vincristine therapy: case report.

Abstract

Vincristine, adriamycin, and dexamethasone (VAD) chemotherapy protocol is first-choice treatment in newly diagnosed multiple myeloma patients in many centers. Sudden hearing loss associated with vincristine therapy is a rarely observed event in the VAD protocol. We describe a 69-year old male patient diagnosed with multiple myeloma 7 months ago who developed sudden bilateral hearing loss related to vincristine therapy. This uncommon adverse effect of vincristine is discussed and the literature reviewed.

• Authors: I Aydogdu, O Ozturan, I Kuku, E Kaya, A Sevinc, R Yildiz
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 12 Issue 6 Pg. 530-2 (Dec 2000) ISSN: 1120-009X [Print] England
• PMID: 11154039 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Phytogenic
• Vincristine
• Dexamethasone
• Doxorubicin

Topics

• Aged
• Antineoplastic Agents, Phytogenic (adverse effects)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Dexamethasone (adverse effects, therapeutic use)
• Doxorubicin (adverse effects, therapeutic use)
• Hearing Loss, Bilateral (chemically induced)
• Humans
• Male
• Multiple Myeloma (drug therapy)
• Vincristine (adverse effects, therapeutic use)